Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma

Frontiers in Oncology

Hao Zhou¹  Yongting Lai²  Yingru Zhi³  Bing Feng³  Mubalake Abudoureyimu³  Ting Wang³  Xiaoyuan Chu³  Rui Wang³  Ping Chen⁴ 

[1] Department of Medical Oncology, Jinling Hospital, Nanjing Medical University, Nanjing, China;Department of Medical Oncology, Nanjing School of Clinical Medicine, Jinling Hospital, Southern Medical University, Nanjing, China;Department of Medical Oncology, School of Medicine, Jinling Hospital, Nanjing University, Nanjing, China;Department of Oncology, First People's Hospital of Yancheng, Fourth Affiliated Hospital of Nantong University, Yancheng, China;

关键词: hepatocellular carcinoma (HCC);    sorafenib resistance;    non-coding RNAs (ncRNAs);    microRNAs (miRNAs);    long non-coding RNAs (lncRNAs);   

DOI  :  10.3389/fonc.2019.01156

来源: DOAJ

【 摘 要 】

As the first oral multi-target anti-tumor drug proved for the treatment of patients with advanced liver cancer in 2007, sorafenib has changed the landscape of advanced hepatocellular carcinoma (HCC) treatment. However, drug resistance largely hinders its clinical application. Non-coding RNAs (ncRNAs), including microRNAs (miRNAs), and long non-coding (lncRNAs), have recently been demonstrated playing critical roles in a variety of cancers including HCC, while the mechanisms of ncRNAs in HCC sorafenib resistance have not been extensively characterized yet. Herein, we summarize the mechanisms of recently reported ncRNAs involved in sorafenib resistance and discuss the potential strategies for their application in the battle against HCC.

【 授权许可】

Unknown